Oramed
 | |
| Company type | Public |
|---|---|
| Nasdaq: ORMP Russell Microcap Index component TASE: ORMP | |
| Industry | Biotech |
| Founded | 2006 |
| Headquarters | |
Key people | Nadav Kidron (CEO) |
| Website | oramed |
Oramed Pharmaceuticals Inc. (Hebrew: אורמד), is a publicly traded company engaged in the development of oral drug delivery systems – most notably an oral insulin capsule for treating type 2 diabetes. The company was founded in 2006 and is headquartered in Jerusalem. Its shares are listed on the NASDAQ Capital Market and the Tel Aviv Stock Exchange.
History
[edit]Oramed Pharmaceuticals was founded in 2006 by Miriam Kidron, a scientist at the Hadassah University Hospital in Jerusalem, and her son Nadav Kidron.[1][2]
Product pipeline
[edit]Oramed considers its flagship product to be an oral insulin capsule developed to treat sufferers of type 2 diabetes. The Company is currently conducting Phase 3 trials, under the FDA, for oral insulin in Type 2 diabetes.
In addition to the oral insulin capsule, Oramed is developing an exenatide-based capsule designed to balance blood sugar levels and control appetite, and is conducting clinical trials for the treatment of NASH with oral insulin.[3]
In 2021, Oramed created a subsidiary, Oravax Medical, to bring an oral Covid-19 vaccine to market.[4]
In January 2023, Phase 3 trial of Oramed's orally administered insulin for Type 2 diabetes patients failed thus causing the share price to plunge.[5] The company has mentioned that the pill worked for a subset of the population and will pursue a Phase 3 trial for that subset. [6]
In May 2023, Ben Shapiro invested $4.7 million and was named to the board of directors.[7]
On May 15, 2023, it was reported that Oramed's insulin pill was approved in China and will work with a Chinese firm to apply for a marketing authorizations. [8]
Subsidiaries
[edit]OraTech Pharmaceuticals is a joint venture formed by Oramed Pharmaceuticals and Hefei Tianhui Biotech, to commercialize its insulin capsule and is expected to list on the NASDAQ sometime in 2025.
See also
[edit]References
[edit]- ^ Weinreb, Gali (15 January 2013). "Insulin pill co Oramed jumps on Nasdaq listing plans". Globes. Retrieved 16 February 2013.
- ^ Blackburn, Nicky (24 June 2007). "Israeli patent moves closer to achieving oral insulin treatment". Israel21c. Retrieved 16 February 2013.
- ^ "Oramed Initiates Phase 2 NASH Trial of Oral Insulin". www.prnewswire.com. Retrieved 26 August 2021.
- ^ "Oramed Forms a Joint Venture, Oravax Medical Inc., for the Development of Novel Oral COVID-19 Vaccines". www.prnewswire.com. Retrieved 26 August 2021.
- ^ "Oramed plunges after reporting trial failure". Globes. Retrieved 4 May 2023.
- ^ "Oramed to reinitiate pivotal type 2 diabetes trial after Phase III flop". clinicaltrialsarena.com. 21 February 2024. Retrieved 3 May 2025.
- ^ "Conservative Pundit Ben Shapiro Invests $4.7 Million in Israeli Drug Company". Bloomberg. Retrieved 4 May 2023.
- ^ "Oramed Announces that its Chinese Partner, HTIT, has Successfully Completed a Phase 3 Oral Insulin Clinical Trial and Submitted a Marketing Authorization Application in China". prnewswire.com. 15 May 2023. Retrieved 3 May 2025.
| Healthcare | |
|---|---|
| Communication & Networks | |
| Software | |
| Electronics | |
| Security & defense | |
| Consumer goods | |
| Conglomerates | |
